Market revenue in 2023 | USD 177.5 million |
Market revenue in 2030 | USD 358.1 million |
Growth rate | 10.5% (CAGR from 2023 to 2030) |
Largest segment | Tavr (transcatheter aortic valve replacement) |
Fastest growing segment | LAAC (Left Atrial Appendage Closure) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure) |
Key market players worldwide | Boston Scientific Corp, Medtronic PLC, Edwards Lifesciences Corp, Abbott Laboratories, St. Jude Medical, LivaNova PLC, Stryker Corp, Lepu Medical, Biomerics, CardioKinetix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to structural heart devices market will help companies and investors design strategic landscapes.
Tavr (transcatheter aortic valve replacement) was the largest segment with a revenue share of 52.39% in 2023. Horizon Databook has segmented the Middle East & Africa structural heart devices market based on savr (surgical aortic valve replacement), tavr (transcatheter aortic valve replacement), mitral repair (annuloplasty), laac (left atrial appendage closure) covering the revenue growth of each sub-segment from 2018 to 2030.
The Middle East and Africa (MEA) region has a significantly growing interest in minimally invasive treatments like TAVI. The driving factors for the structural heart devices market in the MEA region include the increasing prevalence of SHD, the aging population, and the growing awareness and adoption of advanced cardiovascular care technologies.
The region's healthcare infrastructure is improving, with an emphasis on early detection and treatment of SHD, which is facilitated by sophisticated diagnostic networks & well-established healthcare systems. This infrastructure supports the adoption of structural heart devices, including TAVI, which is a less invasive procedure with a lower mortality risk than traditional cardiac surgery.
Moreover, technological advancements have improved procedural outcomes, making it a preferred option for treating severe aortic stenosis and other structural heart conditions. The region's healthcare providers are increasingly recognizing the benefits of TAVI, including its lower risk profile and the ability to treat patients with complex anatomies or those who are not candidates for traditional surgery.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa structural heart devices market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa structural heart devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account